XIST
ECILC
Market cap1.16bUSD
Nov 12, Last price
83.50TRY
Name
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
Chart & performance
P/E
27.39
P/S
5.80
EPS
3.05
Div yield, %
1.41%
Shrs. gr., 5y
—
Rev. gr., 5y
61.12%
Revenues
9.87b
+12.59%
Net income
2.09b
+104.06%
CFO
2.21b
+6.04%
Dividend
May 06, 20261.75116 TRY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a Turkish enterprise, operating predominantly in the health and real estate development sectors through its various subsidiaries. Its Health division is responsible for the production and distribution of pharmaceutical goods for both human and veterinary applications. Concurrently, the Real Estate Development segment is engaged in property creation and offers consultancy pertaining to land development and project oversight. This company, established in Istanbul, Turkey, in 1951, functions as a subsidiary of Eczacibasi Holding A.S.
Related entities
Parent
ECZACIBAŞI HOLDİNG ANONİM ŞİRKETİ
Subsidiaries (2)
EİP ECZACIBAŞI İLAÇ PAZARLAMA ANONİM ŞİRKETİ
GENSENTA İLAÇ SANAYİ VE TİCARET ANONİM ŞİRKETİ
Key people
Canan Bademlioglu
General Manager
Akin D. Dincsoy
Independent Member of the Board
H. Toker Alban
Independent Non-Executive Member of the Board of Directors · since 2018
Legal address
Büyükdere Caddesi Ali Kaya Sokak No:5 Levent İstanbul
İSTANBUL 34394
TR
İSTANBUL 34394
TR
Headquarters
ESENTEPE MAH.ALİ KAYA SOK.NO:5 ŞİŞLİ/İSTANBUL
İSTANBUL 34394
TR
İSTANBUL 34394
TR
Valuation
Title TRY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||